KPDS, “The MFDS’s measure on olmesartan is inadequate”
The prescription policy for olmesartan, a hypertensive treatment, has been re-discussed.
On the 2nd, the Korean Pharmacists for Democratic Society(hereinafter referring to KPDS) emphasized necessity to tighten the prescription policy, as arguing the Ministry of Food and Drug Safety’s(MFDS) chan...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
